Disease stratification in GCA and PMR: state of the art and future perspectives
暂无分享,去创建一个
E. Matteson | A. Tomelleri | B. Dasgupta | C. Dejaco | Y. van Sleen | A. Sebastian | F. Coath | Daniel Robbins | Ksm van der Geest | K. V. D. van der Geest | Muhammad Asim Khurshid | Barbara K. Pierscionek | Muhammad Khurshid
[1] E. Matteson,et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica , 2023, Annals of the rheumatic diseases.
[2] A. Tomelleri,et al. Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study. , 2023, Seminars in arthritis and rheumatism.
[3] A. Tomelleri,et al. Positron Emission Tomography Imaging in Vasculitis. , 2023, Cardiology clinics.
[4] M. Akiyama,et al. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy , 2022, Rheumatology International.
[5] P. Hilliquin,et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. , 2022, JAMA.
[6] A. Diepstra,et al. Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica , 2022, Annals of the Rheumatic Diseases.
[7] T. Kwee,et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica , 2022, Frontiers in Immunology.
[8] P. Heeringa,et al. OP0015 PROINFLAMMATORY MONOCYTES AND MACROPHAGES IN SYNOVIAL FLUID AND BURSAL TISSUE OF PATIENTS WITH POLYMYALGIA RHEUMATICA: POTENT PRODUCERS OF IL-6 AND GM-CSF , 2022, Annals of the Rheumatic Diseases.
[9] L. Hemkens,et al. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. , 2022, Seminars in arthritis and rheumatism.
[10] G. Krönke,et al. Synovial Macrophage and Fibroblast Heterogeneity in Joint Homeostasis and Inflammation , 2022, Frontiers in Medicine.
[11] D. Sinha,et al. Efficacy of leflunomide as a steroid‐sparing agent in treatment of Indian giant cell arteritis patients: A 2‐year follow‐up study , 2022, International journal of rheumatic diseases.
[12] I. Wicks,et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2022, Annals of the Rheumatic Diseases.
[13] P. Heeringa,et al. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica , 2022, Arthritis Research & Therapy.
[14] P. Mandl,et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial , 2022, Annals of the Rheumatic Diseases.
[15] K. Bondensgaard,et al. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis , 2022, Annals of the Rheumatic Diseases.
[16] E. Matteson,et al. Looking ahead: giant-cell arteritis in 10 years time , 2022, Therapeutic advances in musculoskeletal disease.
[17] J. Burns,et al. Global epidemiology of vasculitis , 2021, Nature Reviews Rheumatology.
[18] S. Mackie,et al. A shared basis for overlapping immunopathologies in giant cell arteritis and polymyalgia rheumatica , 2021, The Lancet Rheumatology.
[19] A. Diamantopoulos,et al. The fast-track outpatient clinic significantly decreases hospitalisation rates among polymyalgia rheumatica patients , 2021, BMC Rheumatology.
[20] A. Tomelleri,et al. Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage , 2021, The Lancet Rheumatology.
[21] H. Küçük,et al. Diagnostic utility of serum biomarkers in large vessel vasculitis and their correlation with positron emission tomography. , 2021, Modern rheumatology.
[22] F. V. D. van den Hoogen,et al. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial , 2021, The Lancet Rheumatology.
[23] Ashwini Kini,et al. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis , 2021, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[24] W. Schmidt,et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial , 2021, Trials.
[25] G. Schett,et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases , 2021, Nature Reviews Rheumatology.
[26] G. Guyatt,et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis care & research.
[27] R. Slart,et al. Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica , 2021, Rheumatology.
[28] P. Heeringa,et al. A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis , 2021, Arthritis & rheumatology.
[29] Patrik L. Ståhl,et al. Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis , 2021, Annals of the Rheumatic Diseases.
[30] A. Tomelleri,et al. Current and innovative therapeutic strategies for the treatment of giant cell arteritis , 2021 .
[31] J. Stone,et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial , 2021 .
[32] S. Hayreh. Giant cell arteritis: Its ophthalmic manifestations , 2021, Indian journal of ophthalmology.
[33] J. Maillefert,et al. The frequency of occult solid malignancy in patients with polymyalgia rheumatica-like symptoms , 2021, Therapeutic advances in musculoskeletal disease.
[34] F. Jamar,et al. Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[35] A. Tomelleri,et al. Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss , 2020, Rheumatology.
[36] G. Fragoulis,et al. Correspondence on ‘Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia’ , 2020, Annals of the Rheumatic Diseases.
[37] J. Pope,et al. A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.
[38] C. Dejaco,et al. New insights into the role of imaging in polymyalgia rheumatica. , 2020, Rheumatology.
[39] A. Tomelleri,et al. Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. , 2020, RMD open.
[40] C. Prati,et al. Prognostic Value of 18F-Fluorodeoxyglucose PET-CT score at baseline on the therapeutic response to prednisone in patients with polymyalgia rheumatica. , 2020, Joint bone spine.
[41] A. Scott,et al. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica , 2020, International journal of rheumatic diseases.
[42] P. Heeringa,et al. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis , 2020, Clinical & translational immunology.
[43] E. Matteson,et al. Polymyalgia Rheumatica and Giant Cell Arteritis. , 2020, JAMA.
[44] J. Jackson,et al. Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA) , 2020, BMC Rheumatology.
[45] S. Mackie,et al. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis , 2020, JAMA internal medicine.
[46] C. Turesson,et al. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. , 2020, Seminars in arthritis and rheumatism.
[47] K. Amano,et al. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. , 2020, Rheumatology.
[48] C. Crowson,et al. Giant cell arteritis and its mimics: A comparison of three patient cohorts. , 2020, Seminars in arthritis and rheumatism.
[49] T. Horita,et al. Gadolinium-enhanced magnetic resonance imaging in shoulders contributes accurate diagnosis and predicting recurrence to patients with polymyalgia rheumatica. , 2020, Clinical and experimental rheumatology.
[50] C. Fraser,et al. Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis , 2020, International journal of rheumatic diseases.
[51] K. Akashi,et al. Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica , 2020, Rheumatology International.
[52] M. Okano,et al. Cohort Study , 2020, Definitions.
[53] M. Isobe,et al. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions , 2020, Arthritis Research & Therapy.
[54] R. Luqmani,et al. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia , 2020, Annals of the rheumatic diseases.
[55] F. Orsini,et al. Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis , 2019, Clinical Rheumatology.
[56] F. Buttgereit,et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis , 2019, RMD Open.
[57] A. Aouba,et al. Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. , 2019, Journal of autoimmunity.
[58] P. Merkel,et al. Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis , 2019, The Journal of Rheumatology.
[59] A. Boots,et al. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica , 2019, Front. Immunol..
[60] A. Boots,et al. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. , 2019, Rheumatology.
[61] C. Turesson,et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.
[62] A. Versari,et al. Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. , 2019, Seminars in arthritis and rheumatism.
[63] Courtney A. Roberts,et al. Economic and objective burden of caregiving on informal caregivers of patients with systemic vasculitis. , 2019, Musculoskeletal care.
[64] A. Saraux,et al. Localized Myofascial Inflammation Revealed by Magnetic Resonance Imaging in Recent-onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy , 2019, The Journal of Rheumatology.
[65] A. Boots,et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis , 2019, Rheumatology.
[66] M. González-Gay,et al. Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. , 2019, Seminars in arthritis and rheumatism.
[67] M. Recher,et al. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses , 2019, Annals of the rheumatic diseases.
[68] B. Griffiths,et al. Giant cell arteritis: new concepts, treatments and the unmet need that remains. , 2018, Rheumatology.
[69] K. Goffin,et al. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica—A prospective study of 99 patients , 2018, Rheumatology.
[70] B. Dasgupta,et al. Current and emerging therapies in large-vessel vasculitis. , 2018, Rheumatology.
[71] G. Thallinger,et al. Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patients , 2018, Clinical Rheumatology.
[72] M. Tomšič,et al. Does leflunomide have a role in giant cell arteritis? An open-label study , 2018, Clinical Rheumatology.
[73] C. Kallenberg,et al. Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018, Arthritis & rheumatology.
[74] D. Bluemke,et al. F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis , 2018 .
[75] B. Bonnotte,et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. , 2018, Autoimmunity reviews.
[76] Eric L Matteson,et al. Large-vessel giant cell arteritis: diagnosis, monitoring and management , 2018, Rheumatology.
[77] A. Scott,et al. Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica , 2018, Rheumatology.
[78] W. Schmidt. Ultrasound in the diagnosis and management of giant cell arteritis , 2018, Rheumatology.
[79] J. Rizzo,et al. Ophthalmic manifestations of giant cell arteritis. , 2018, Rheumatology.
[80] A. Saraux,et al. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab , 2018, Arthritis Research & Therapy.
[81] A. Iagnocco,et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.
[82] M. Alba,et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients , 2017, RMD Open.
[83] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[84] J. Stone,et al. Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.
[85] J. Krischer,et al. A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.
[86] B. Bonnotte,et al. Giant Cell Arteritis–related Stroke: A Retrospective Multicenter Case-control Study , 2017, The Journal of Rheumatology.
[87] L. Cimino,et al. Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. , 2017, Journal of autoimmunity.
[88] G. Ferraccioli,et al. Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study , 2017, The Journal of Rheumatology.
[89] Z. Bortlíček,et al. PET/CT imaging in polymyalgia rheumatica: praepubic 18F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis , 2017, Radiology and oncology.
[90] M. Broder,et al. Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. , 2016, Seminars in arthritis and rheumatism.
[91] E. Matteson,et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.
[92] B. Bonnotte,et al. Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. , 2016, Journal of autoimmunity.
[93] D. Huglo,et al. F-fluorodeoxyglucose positron emission of subsequent aortic complications in giant-cell arteritis , 2016 .
[94] J. Serfaty,et al. Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. , 2016, Autoimmunity reviews.
[95] M. Tomšič,et al. Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis , 2016, Medicine.
[96] H. Marques,et al. Acute upper limb ischemia, a rare presentation of giant cell arteritis. , 2016, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[97] R. Pathak,et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. , 2016, Clinical and experimental rheumatology.
[98] E. Matteson,et al. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. , 2016, Rheumatic diseases clinics of North America.
[99] P. Emery,et al. Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids , 2015, Annals of the rheumatic diseases.
[100] K. Barraclough,et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2015, Annals of the rheumatic diseases.
[101] R. Quirce,et al. (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. , 2015, Revista espanola de medicina nuclear e imagen molecular.
[102] A. Boots,et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. , 2015, Rheumatology.
[103] Stephen G. Martin,et al. Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation , 2015, Arthritis Research & Therapy.
[104] U. Hoffmann,et al. Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. , 2015, Journal of vascular surgery.
[105] P. Gregersen,et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. , 2015, American journal of human genetics.
[106] E. Matteson,et al. Large-vessel giant cell arteritis: a cohort study. , 2015, Rheumatology.
[107] H. Petri,et al. Incidence of Giant Cell Arteritis and Characteristics of Patients: Data‐Driven Analysis of Comorbidities , 2015, Arthritis care & research.
[108] B. Dasgupta,et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. , 2015, Clinical and experimental rheumatology.
[109] A. Hewitt,et al. Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050 , 2015, The Journal of Rheumatology.
[110] M. Alba,et al. Relapses in Patients With Giant Cell Arteritis , 2014, Medicine.
[111] P. Merkel,et al. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden , 2014, Annals of the rheumatic diseases.
[112] M. Perretti,et al. Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression , 2014, Circulation research.
[113] B. Sheehan,et al. A 12-month follow-up study of people with dementia referred to general hospital liaison psychiatry services. , 2013, Age and ageing.
[114] F. Paparo,et al. High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. , 2013, Rheumatology.
[115] J. Moghimi,et al. Efficacy of methotrexate in patients with polymyalgia rheumatica , 2013 .
[116] W. Stone,et al. Inflammatory aneurysms treated with EVAR. , 2012, Seminars in vascular surgery.
[117] B. Bonnotte,et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. , 2012, Arthritis and rheumatism.
[118] Mahboob Rahman,et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis , 2012, Annals of the rheumatic diseases.
[119] B. Dasgupta,et al. Efficacy and tolerability of leflunomide in difficult‐to‐treat polymyalgia rheumatica and giant cell arteritis: a case series , 2012, International journal of clinical practice.
[120] D. Klatzmann,et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. , 2012, Arthritis and rheumatism.
[121] A. Iagnocco,et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.
[122] G. Deshpande,et al. Clinical Characteristics of Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema Compared to Patients with Pure Polymyalgia Rheumatica , 2012, The Journal of Rheumatology.
[123] L. Crofford,et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. , 2011, Clinical therapeutics.
[124] E. Matteson,et al. Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly , 2011 .
[125] M. González-Gay,et al. Relapses and Recurrences in Giant Cell Arteritis: A Population-Based Study of Patients With Biopsy-Proven Disease From Northwestern Spain , 2011, Medicine.
[126] G. Garlaschi,et al. Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: a magnetic resonance imaging study. , 2011, Rheumatology.
[127] B. Preston,et al. Case Series , 2010, Toxicologic pathology.
[128] R. Olshen,et al. Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.
[129] C. Salvarani,et al. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. , 2009, Rheumatology.
[130] M. González-Gay,et al. Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis , 2009, Medicine.
[131] A. Cerulli,et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. , 2009, Respiratory medicine.
[132] Jiusheng Deng,et al. Toll-Like Receptors 4 and 5 Induce Distinct Types of Vasculitis , 2009, Circulation research.
[133] C. Leonardi,et al. Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: Preliminary results of an open randomized study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[134] N. Nishimoto,et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.
[135] W. Thomson,et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. , 2008, Rheumatology.
[136] Olga Pryshchep,et al. Vessel-Specific Toll-Like Receptor Profiles in Human Medium and Large Arteries , 2008, Circulation.
[137] M. Langer,et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. , 2008, Arthritis and rheumatism.
[138] M. Sonnenblick,et al. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. , 2008, Clinical and experimental rheumatology.
[139] I. Olivieri,et al. Cervical interspinous bursitis in active polymyalgia rheumatica , 2008, Annals of the rheumatic diseases.
[140] A. Hutchings,et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? , 2007, Rheumatology.
[141] A. Radjenovic,et al. Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[142] P. Merkel,et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.
[143] A. Cipriani,et al. What is an individual patient data meta-analysis? , 2007, Epidemiologia e Psichiatria Sociale.
[144] K. Chakravarty,et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. , 2007, Arthritis and rheumatism.
[145] Mark Stevenson,et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. , 2007, Health technology assessment.
[146] H. Kleinman,et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. , 2006, Rheumatology.
[147] G. Hunder. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. , 2006, Mayo Clinic proceedings.
[148] L. Mortelmans,et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.
[149] L. Mortelmans,et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. , 2005, Rheumatology.
[150] D. Consonni,et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. , 2005, Arthritis and rheumatism.
[151] M. Vinceti,et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. , 2005, Arthritis and rheumatism.
[152] R. Caporali,et al. Prednisone plus Methotrexate for Polymyalgia Rheumatica , 2004, Annals of Internal Medicine.
[153] T. Tedder,et al. Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis , 2004, The Journal of experimental medicine.
[154] D. Colomer,et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.
[155] W. Ollier,et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. , 2003, Seminars in arthritis and rheumatism.
[156] F. Strutz,et al. Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[157] K. Kalunian,et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.
[158] J. Fernandez-Solà,et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. , 2002, Arthritis and rheumatism.
[159] R. Caporali,et al. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study , 2001, Annals of the rheumatic diseases.
[160] M. Peterson,et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.
[161] G. Gran. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis - A prospective two-year study in 273 patients , 2001, Scandinavian journal of rheumatology.
[162] C. Cooper,et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.
[163] I. Olivieri,et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. , 2000, Seminars in arthritis and rheumatism.
[164] I. Olivieri,et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. , 1998, Arthritis and rheumatism.
[165] C. Salvarani,et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. , 1996, Arthritis and rheumatism.
[166] G. A. van Albada-Kuipers,et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? , 1996, Annals of the rheumatic diseases.
[167] F. Salaffi,et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. , 1996, The Journal of rheumatology.
[168] G. Hunder,et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. , 1994, Arthritis and rheumatism.
[169] G. Panayi,et al. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. , 1990, British journal of rheumatology.
[170] L. A. Healey,et al. Polymyalgia rheumatica and giant cell arteritis. , 1984, The Western journal of medicine.
[171] 高井 俊夫. 奇形・脳性麻痺の起因に関するprospective follow up studyについて , 1966 .
[172] T. Landberg,et al. INVOLVEMENT OF LARGE VESSELS IN POLYMYALGIA ARTERITICA. , 1965, Lancet.
[173] OUP accepted manuscript , 2021, Rheumatology.
[174] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[175] P. Heeringa,et al. What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018 .
[176] G. Haugeberg,et al. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? , 2016, Rheumatology.
[177] N. Arden,et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.
[178] Javier Martín,et al. Genetic component of giant cell arteritis. , 2014, Rheumatology.
[179] J. Manson,et al. Prospective Study of , 2007 .
[180] R. Caporali,et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. , 2004, Annals of internal medicine.
[181] Thomas R. Riley,et al. A Randomized Double-blind Placebo-controlled Trial , 2004 .
[182] Teresa Foo,et al. : SYSTEMATIC LITERATURE REVIEW , 2004 .
[183] P. Toutouzas,et al. A Magnetic Resonance Imaging Study , 2003 .
[184] E. Gromnica-ihle,et al. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. , 2002, Rheumatology.
[185] J. Noval Menéndez,et al. [Distal musculo-skeletal manifestations in rheumatic polymyalgia]. , 2002, Revista clinica espanola.
[186] A. Arnold. Ischemic optic neuropathies. , 2001, Ophthalmology clinics of North America.
[187] D. Bacal. Re: Caldeira JAF: Stage I intraoperative adjustment of eye muscle surgery forexodeviations based on eye position during general anesthesia: a prospective study of 35 patients. , 1998, Binocular vision & strabismus quarterly.
[188] A. de la Sierra,et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. , 1998, Arthritis and rheumatism.
[189] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.